Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12227
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBranford, Susanen
dc.contributor.authorYeung, David Ten
dc.contributor.authorParker, Wendy Ten
dc.contributor.authorRoberts, Nicola Den
dc.contributor.authorPurins, Leanneen
dc.contributor.authorBraley, Jodi Aen
dc.contributor.authorAltamura, Haley Ken
dc.contributor.authorYeoman, Alexandra Len
dc.contributor.authorGeorgievski, Jasminaen
dc.contributor.authorJamison, Bronte Aen
dc.contributor.authorPhillis, Stuarten
dc.contributor.authorDonaldson, Zoeen
dc.contributor.authorLeong, Maryen
dc.contributor.authorFletcher, Lindaen
dc.contributor.authorSeymour, John Fen
dc.contributor.authorGrigg, Andrew P en
dc.contributor.authorRoss, David Men
dc.contributor.authorHughes, Timothy Pen
dc.date.accessioned2015-05-16T01:53:04Z
dc.date.available2015-05-16T01:53:04Z
dc.date.issued2014-05-23en
dc.identifier.citationBlood 2014; 124(4): 511-8en
dc.identifier.govdoc24859364en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12227en
dc.description.abstractIn chronic myeloid leukemia (CML) patients, a breakpoint cluster region-Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes. We investigated 528 first-line imatinib-treated patients to determine whether patients with the poorest outcome can be better discriminated at 3 months. All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months (P < .001). However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 >10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Patients with BCR-ABL1 halving time <76 days (n = 74) had significantly superior outcomes compared with patients whose BCR-ABL1 values did not halve by 76 days (n = 21; 4-year overall survival, 95% vs 58%, P = .0002; progression-free survival, 92% vs 63%, P = .008; failure-free survival, 59% vs 6%, P < .0001; and major molecular response, 54% vs 5%, P = .008). By multivariate analysis, the halving time was an independent predictor of outcome in this poor risk group. Our study highlighted that the rate of BCR-ABL1 decline may be a critical prognostic discriminator of the patients with very poor outcome among those >10% at 3 months. The International Randomized IFN vs STI571 (IRIS) trial was registered at http://www.clinicaltrials.gov as #NCT00006343. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) trial was registered at http://www.clinicaltrials.gov as #NCT00124748. The Therapeutic Intensification in DE-novo Leukaemia (TIDEL) I trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000614493. The TIDEL II trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000325404.en
dc.language.isoenen
dc.subject.otherAntineoplastic Agents.therapeutic useen
dc.subject.otherBenzamides.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherFusion Proteins, bcr-abl.genetics.metabolismen
dc.subject.otherHumansen
dc.subject.otherLeukemia, Myelogenous, Chronic, BCR-ABL Positive.drug therapy.metabolism.mortalityen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPiperazines.therapeutic useen
dc.subject.otherPrognosisen
dc.subject.otherPyrimidines.therapeutic useen
dc.subject.otherRemission Inductionen
dc.subject.otherSurvival Rateen
dc.subject.otherTime Factorsen
dc.titlePrognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.en
dc.typeJournal Articleen
dc.identifier.journaltitleBlooden
dc.identifier.affiliationDepartment of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australiaen
dc.identifier.affiliationUniversity of Melbourne, Parkville, Australiaen
dc.identifier.affiliationDepartment of Haematology, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Haematology, Flinders University and Medical Centre, Bedford Park, Australiaen
dc.identifier.affiliationDepartment of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australiaen
dc.identifier.affiliationSchool of Pharmacy and Medical Science, University of South Adelaide, Adelaide, Australiaen
dc.identifier.affiliationSchool of Medicine, and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australiaen
dc.identifier.affiliationSchool of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australiaen
dc.identifier.affiliationCancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australiaen
dc.identifier.affiliationAustralasian Leukaemia and Lymphoma Group, East Melbourne, Australiaen
dc.identifier.affiliationSchool of Medicine, and Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australiaen
dc.identifier.doi10.1182/blood-2014-03-566323en
dc.description.pages511-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24859364en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
24859364.pdf867.41 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

12
checked on Mar 28, 2024

Download(s)

68
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.